Rare lephants
Screener

Cogent Biosciences, Inc.

COGT ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Cogent Biosciences, Inc.

Total Moat Score 7 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Bezuclastinib is a patent-protected, purpose-designed KIT D816V inhibitor with strong Phase 3 data, though it remains pre-approval in most indications.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 No manufacturing or cost advantage exists; clinical-stage biotechs compete on data and IP, not production cost.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 2 / 5 If approved, specialty oncology/rare-disease drugs typically command strong list pricing, though Cogent would enter as a second mover behind Blueprint Medicines' Ayvakit.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 No network effect applies to a clinical-stage pharmaceutical asset.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 Once physicians and patients are established on a KIT-inhibitor regimen, some switching friction exists, but this benefits the incumbent (Blueprint) more than Cogent today.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 Systemic mastocytosis and imatinib-resistant GIST are rare-disease niches that may not support many competing targeted therapies, offering a modest scale barrier once approved.